Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for September 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
PAD-4 Antibodies May Predict Future Rheumatoid Arthritis
THURSDAY, Sept. 30 (HealthDay News) -- Antibodies against peptidyl arginine deiminase type 4 (PAD-4) are a specific early marker of rheumatoid arthritis (RA), according to research published in the September issue of Arthritis & Rheumatism.
Tanezumab Is Effective Osteoarthritis Treatment
WEDNESDAY, Sept. 29 (HealthDay News) -- Tanezumab, a monoclonal antibody that binds and inhibits nerve growth factor, appears to relieve joint pain enough to improve function in people with osteoarthritis of the knee, according to research published online Sept. 29 in the New England Journal of Medicine.
Assaults Linked to Pain in Nursing Home Workers
WEDNESDAY, Sept. 29 (HealthDay News) -- Many care providers in nursing homes report recent physical assaults in the workplace, and these are associated in a dose-response manner with musculoskeletal pain, according to research published online Sept. 27 in Occupational and Environmental Medicine.
Anger, Sadness Increase Pain in Women With Fibromyalgia
TUESDAY, Sept. 28 (HealthDay News) -- Negative emotions increase pain responses in women with and without fibromyalgia (FM), while combined treatment with cognitive behavioral therapy and a tailored exercise program can improve outcome in FM, according to two studies published in the October issue of Arthritis Care & Research.
Anti-Apo A-1 Marker for Cardiac Events in RA Patients
TUESDAY, Sept. 28 (HealthDay News) -- An IgG antibody called anti-apolipoprotein A-1 (anti-Apo A-1) is predictive of major cardiovascular events in patients with rheumatoid arthritis (RA), according to research published in the September issue of Arthritis & Rheumatism.
Exercise Preserves Functioning in Women With Osteopenia
TUESDAY, Sept. 28 (HealthDay News) -- An exercise program in elderly women with osteopenia appears to preserve physical functioning and decrease the risk of fractures and mortality, according to a study in the Sept. 27 issue of the Archives of Internal Medicine.
RA May Raise Complication Risk After Ankle Arthroplasty
MONDAY, Sept. 27 (HealthDay News) -- Underlying inflammatory connective-tissue disease, primarily rheumatoid arthritis, is associated with an increased risk for major incision complications and additional surgery for patients who have undergone total ankle arthroplasty, according to research published in the Sept. 15 issue of the Journal of Bone & Joint Surgery.
Rituximab Infection Risk in Daily Practice Same As in Trials
FRIDAY, Sept. 24 (HealthDay News) -- The rate of severe infections in rheumatoid arthritis (RA) patients treated with rituximab (RTX) in daily practice is similar to that seen in controlled clinical trials of the drug, according to research published in the September issue of Arthritis & Rheumatism. The study also identifies patient characteristics which are associated with an increased risk of these infections.
Daily 100 mg Milnacipran Found Effective in Fibromyalgia
THURSDAY, Sept. 23 (HealthDay News) -- Milnacipran at a dosage of 100 mg daily decreases pain and several other symptoms of fibromyalgia, according to research published in the September issue of Arthritis & Rheumatism.
Spleen Tyrosine Kinase Inhibitor Benefits RA Patients
WEDNESDAY, Sept. 22 (HealthDay News) -- A spleen tyrosine kinase (Syk) inhibitor significantly reduces rheumatoid arthritis (RA) disease activity in patients not responding to methotrexate, according to a study published online Sept. 22 in the New England Journal of Medicine.
Glucosamine, Chondroitin Not Effective for Osteoarthritis
FRIDAY, Sept. 17 (HealthDay News) -- Glucosamine, chondroitin, or a combination of the two does not appear to reduce joint pain associated with osteoarthritis or have an impact on narrowing of the joint space, according to research published online Sept. 16 in BMJ.
Krystexxa Approved for Gout
WEDNESDAY, Sept. 15 (HealthDay News) -- Krystexxa (pegloticase) has been approved by the U.S. Food and Drug Administration for adults with gout who do not respond to, or who cannot tolerate, standard treatments.
Depression, Burnout Have Dire Impact on Medical Training
TUESDAY, Sept. 14 (HealthDay News) -- Depressed medical students are more likely to endorse depression stigma attitudes than nondepressed students, and those with burnout are more likely to engage in unprofessional conduct and less likely to hold altruistic views of physicians' social responsibilities than those without burnout, according to two articles published in the Sept. 15 issue of the Journal of the American Medical Association.
Sacrifice Makes Industry Gifts Seem More Acceptable
TUESDAY, Sept. 14 (HealthDay News) -- Residents who are reminded of the sacrifices they made to attain their medical education tend to rate the acceptability of industry-sponsored gifts higher than those who are not reminded, according to research published in the Sept. 15 issue of the Journal of the American Medical Association.
Re-Consent Important Before Secondary Use of Genetic Data
MONDAY, Sept. 13 (HealthDay News) -- Most research participants want to be asked for secondary consent -- referred to as re-consent -- before their existing personal genetic data are added to the federal database of Genotypes and Phenotypes (dbGaP), according to research published in the September issue of the Journal of Empirical Research on Human Research Ethics.
Annual Medical Liability Costs Surpass $50 Billion
THURSDAY, Sept. 9 (HealthDay News) -- The annual costs of the medical liability system in the United States total more than $50 billion, which accounts for a relatively small but non-trivial portion of total health care spending, according to an article in the September issue of Health Affairs.
Platelet Activation Investigated in Pathogenesis of Lupus
THURSDAY, Sept. 2 (HealthDay News) -- Platelet activation may play an important role in the pathogenesis of systemic lupus erythematosus (SLE), and it may present a target for therapy for the disease, according to research published in the Sept. 1 issue of Science Translational Medicine.
Copyright © 2010 ScoutNews, LLC. All rights reserved.
|Previous: September 2010 Briefing - Pulmonology||Next: September 2010 Briefing - Surgery|
Reader comments on this article are listed below. Review our comments policy.